These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

360 related articles for article (PubMed ID: 35140181)

  • 1. CCR8-targeted specific depletion of clonally expanded Treg cells in tumor tissues evokes potent tumor immunity with long-lasting memory.
    Kidani Y; Nogami W; Yasumizu Y; Kawashima A; Tanaka A; Sonoda Y; Tona Y; Nashiki K; Matsumoto R; Hagiwara M; Osaki M; Dohi K; Kanazawa T; Ueyama A; Yoshikawa M; Yoshida T; Matsumoto M; Hojo K; Shinonome S; Yoshida H; Hirata M; Haruna M; Nakamura Y; Motooka D; Okuzaki D; Sugiyama Y; Kinoshita M; Okuno T; Kato T; Hatano K; Uemura M; Imamura R; Yokoi K; Tanemura A; Shintani Y; Kimura T; Nonomura N; Wada H; Mori M; Doki Y; Ohkura N; Sakaguchi S
    Proc Natl Acad Sci U S A; 2022 Feb; 119(7):. PubMed ID: 35140181
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting tumor-infiltrating CCR8
    Chen Q; Shen M; Yan M; Han X; Mu S; Li Y; Li L; Wang Y; Li S; Li T; Wang Y; Wang W; Wei Z; Hu C; Jin A
    J Transl Med; 2024 Jul; 22(1):709. PubMed ID: 39080766
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic depletion of CCR8
    Van Damme H; Dombrecht B; Kiss M; Roose H; Allen E; Van Overmeire E; Kancheva D; Martens L; Murgaski A; Bardet PMR; Blancke G; Jans M; Bolli E; Martins MS; Elkrim Y; Dooley J; Boon L; Schwarze JK; Tacke F; Movahedi K; Vandamme N; Neyns B; Ocak S; Scheyltjens I; Vereecke L; Nana FA; Merchiers P; Laoui D; Van Ginderachter JA
    J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33589525
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fc-Optimized Anti-CCR8 Antibody Depletes Regulatory T Cells in Human Tumor Models.
    Campbell JR; McDonald BR; Mesko PB; Siemers NO; Singh PB; Selby M; Sproul TW; Korman AJ; Vlach LM; Houser J; Sambanthamoorthy S; Lu K; Hatcher SV; Lohre J; Jain R; Lan RY
    Cancer Res; 2021 Jun; 81(11):2983-2994. PubMed ID: 33757978
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differential expression of CCR8 in tumors versus normal tissue allows specific depletion of tumor-infiltrating T regulatory cells by GS-1811, a novel Fc-optimized anti-CCR8 antibody.
    Weaver JD; Stack EC; Buggé JA; Hu C; McGrath L; Mueller A; Wong M; Klebanov B; Rahman T; Kaufman R; Fregeau C; Spaulding V; Priess M; Legendre K; Jaffe S; Upadhyay D; Singh A; Xu CA; Krukenberg K; Zhang Y; Ezzyat Y; Saddier Axe D; Kuhne MR; Meehl MA; Shaffer DR; Weist BM; Wiederschain D; Depis F; Gostissa M
    Oncoimmunology; 2022; 11(1):2141007. PubMed ID: 36352891
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Selective depletion of tumor-infiltrating regulatory T cells with BAY 3375968, a novel Fc-optimized anti-CCR8 antibody.
    Roider HG; Hoff S; Tseng SY; Berndt S; Trautwein M; Filarsky K; Gritzan U; Camps J; Nadler WM; Grudzinska-Goebel J; Ellinger P; Pesch T; Soon CF; Geyer M; Gluske K; Stelte-Ludwig B; Gorjánácz M
    Clin Exp Med; 2024 Jun; 24(1):122. PubMed ID: 38856863
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting CCR8 Induces Protective Antitumor Immunity and Enhances Vaccine-Induced Responses in Colon Cancer.
    Villarreal DO; L'Huillier A; Armington S; Mottershead C; Filippova EV; Coder BD; Petit RG; Princiotta MF
    Cancer Res; 2018 Sep; 78(18):5340-5348. PubMed ID: 30026324
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CD4
    Liu S; Tao Z; Lou J; Li R; Fu X; Xu J; Wang T; Zhang L; Shang W; Mao Y; Wang F
    J Transl Med; 2023 Nov; 21(1):803. PubMed ID: 37950246
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CCR8 marks highly suppressive Treg cells within tumours but is dispensable for their accumulation and suppressive function.
    Whiteside SK; Grant FM; Gyori DS; Conti AG; Imianowski CJ; Kuo P; Nasrallah R; Sadiyah F; Lira SA; Tacke F; Eil RL; Burton OT; Dooley J; Liston A; Okkenhaug K; Yang J; Roychoudhuri R
    Immunology; 2021 Aug; 163(4):512-520. PubMed ID: 33838058
    [TBL] [Abstract][Full Text] [Related]  

  • 10. S-531011, a Novel Anti-Human CCR8 Antibody, Induces Potent Antitumor Responses through Depletion of Tumor-Infiltrating CCR8-Expressing Regulatory T Cells.
    Nagira Y; Nagira M; Nagai R; Nogami W; Hirata M; Ueyama A; Yoshida T; Yoshikawa M; Shinonome S; Yoshida H; Haruna M; Miwa H; Chatani N; Ohkura N; Wada H; Tanaka H
    Mol Cancer Ther; 2023 Sep; 22(9):1063-1072. PubMed ID: 37420296
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In situ analysis of CCR8
    Hayashi Y; Ueyama A; Funaki S; Jinushi K; Higuchi N; Morihara H; Hirata M; Nagira Y; Saito T; Kawashima A; Iwahori K; Shintani Y; Wada H
    BMC Cancer; 2024 May; 24(1):627. PubMed ID: 38783281
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunotherapy Targeting CCR8+ Regulatory T Cells Induces Antitumor Effects via Dramatic Changes to the Intratumor CD8+ T Cell Profile.
    Ueyama A; Nogami W; Nashiki K; Haruna M; Miwa H; Hagiwara M; Nagira M; Wada H; Nagira Y
    J Immunol; 2023 Aug; 211(4):673-682. PubMed ID: 37350632
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preclinical development of a novel CCR8/CTLA-4 bispecific antibody for cancer treatment by disrupting CTLA-4 signaling on CD8 T cells and specifically depleting tumor-resident Tregs.
    Guo C; Dai X; Du Y; Xiong X; Gui X
    Cancer Immunol Immunother; 2024 Aug; 73(10):210. PubMed ID: 39123089
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The impact of CCR8+ regulatory T cells on cytotoxic T cell function in human lung cancer.
    Haruna M; Ueyama A; Yamamoto Y; Hirata M; Goto K; Yoshida H; Higuchi N; Yoshida T; Kidani Y; Nakamura Y; Nagira M; Kawashima A; Iwahori K; Shintani Y; Ohkura N; Wada H
    Sci Rep; 2022 Mar; 12(1):5377. PubMed ID: 35354899
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CCR8 blockade primes anti-tumor immunity through intratumoral regulatory T cells destabilization in muscle-invasive bladder cancer.
    Wang T; Zhou Q; Zeng H; Zhang H; Liu Z; Shao J; Wang Z; Xiong Y; Wang J; Bai Q; Xia Y; Wang Y; Liu L; Zhu Y; Xu L; Dai B; Guo J; Chang Y; Wang X; Xu J
    Cancer Immunol Immunother; 2020 Sep; 69(9):1855-1867. PubMed ID: 32367308
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-CCR4 mAb selectively depletes effector-type FoxP3+CD4+ regulatory T cells, evoking antitumor immune responses in humans.
    Sugiyama D; Nishikawa H; Maeda Y; Nishioka M; Tanemura A; Katayama I; Ezoe S; Kanakura Y; Sato E; Fukumori Y; Karbach J; Jäger E; Sakaguchi S
    Proc Natl Acad Sci U S A; 2013 Oct; 110(44):17945-50. PubMed ID: 24127572
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A GMCSF-Neuroantigen Tolerogenic Vaccine Elicits Systemic Lymphocytosis of CD4
    Moorman CD; Curtis AD; Bastian AG; Elliott SE; Mannie MD
    Front Immunol; 2018; 9():3119. PubMed ID: 30687323
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumor-derived exosomes drive pre-metastatic niche formation in lung via modulating CCL1
    Wang M; Qin Z; Wan J; Yan Y; Duan X; Yao X; Jiang Z; Li W; Qin Z
    Cancer Immunol Immunother; 2022 Nov; 71(11):2717-2730. PubMed ID: 35428909
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Novel Prognostic Biomarker CCR8 for Gastric Cancer and Anti-CCR8 Blockade Attenuate the Immunosuppressive Capacity of Tregs
    Zhang Z; Wang G; Shao X; Wu H; Su X; Zhu L; Ji Z
    Cancer Biother Radiopharm; 2023 Aug; 38(6):415-424. PubMed ID: 37102694
    [No Abstract]   [Full Text] [Related]  

  • 20. Analysis of the T-cell receptor repertoires of tumor-infiltrating conventional and regulatory T cells reveals no evidence for conversion in carcinogen-induced tumors.
    Hindley JP; Ferreira C; Jones E; Lauder SN; Ladell K; Wynn KK; Betts GJ; Singh Y; Price DA; Godkin AJ; Dyson J; Gallimore A
    Cancer Res; 2011 Feb; 71(3):736-46. PubMed ID: 21156649
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.